Related Experiment Video
Updated: Sep 29, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Inconsistent Country-Wide Reporting of Adverse Drug Reactions to Antimicrobials in Sierra Leone (2017-2021): A
Fawzi Thomas1,2, Onome T Abiri1,2, James P Komeh1,2
1National Pharmacovigilance Center, Pharmacy Board of Sierra Leone, Freetown 02717, Sierra Leone.
Abstract:
Background: Monitoring of adverse drug reactions (ADRs) to antimicrobials is important, as they can cause life-threatening illness, permanent disabilities, and death. We assessed country-wide ADR reporting on antimicrobials and their outcomes. Methods: A cross-sectional study was conducted using individual case safety reports (ICSRs) entered into the national pharmacovigilance database (VigiFlow) during 2017−2021. Results: Of 566 ICSRs, inconsistent reporting was seen, with the highest reporting in 2017 and 2019 (mass drug campaigns for deworming), zero reporting in 2018 (reasons unknown), and only a handful in 2020 and 2021 (since COVID-19). Of 566 ICSRs, 90% were for antiparasitics (actively reported during mass campaigns), while the rest (passive reporting from health facilities) included 8% antibiotics, 7% antivirals, and 0.2% antifungals. In total, 90% of the reports took >30 days to be entered (median = 165; range 2−420 days), while 44% had <75% of all variables filled in (desired target = 100%). There were 10 serious ADRs, 18 drug withdrawals, and 60% of ADRs affected the gastrointestinal system. The patient outcomes (N-566) were: recovered (59.5%), recovering (35.5%), not recovered (1.4%), death (0.2%), and unknown (3.4%). There was no final ascertainment of ‘recovering’ outcomes. Conclusions: ADR reporting is inconsistent, with delays and incomplete data. This is a wake-up call for introducing active reporting and setting performance targets.
Insights
Adverse drug reaction reporting for antimicrobials is inconsistent, delayed, and incomplete. Active reporting and performance targets are crucial for improving patient safety and monitoring drug effects.
Area of Science:
- Pharmacovigilance and Drug Safety
- Antimicrobial Therapeutics
- Public Health Monitoring
Background:
- Adverse drug reactions (ADRs) to antimicrobials pose significant health risks, including severe illness and mortality.
- Effective monitoring of antimicrobial ADRs is essential for patient safety and public health.
- This study evaluates the landscape of country-wide antimicrobial ADR reporting and associated patient outcomes.
Purpose of the Study:
- To assess the completeness, timeliness, and consistency of antimicrobial adverse drug reaction (ADR) reporting.
- To analyze the types of antimicrobials reported and the outcomes of ADRs.
- To identify areas for improvement in pharmacovigilance systems for antimicrobials.
Main Methods:
- A cross-sectional study utilizing individual case safety reports (ICSRs) from a national pharmacovigilance database (VigiFlow) between 2017 and 2021.
- Analysis of reporting trends, antimicrobial classes, data completeness, reporting delays, and patient outcomes.
- Categorization of ADRs based on antimicrobial type and affected systems.
Main Results:
- Inconsistent reporting patterns observed, with peaks during mass drug campaigns and minimal reporting in other years.
- Antiparasitics dominated reports (90%), with antibiotics, antivirals, and antifungals comprising smaller proportions.
- Significant reporting delays (median 165 days) and data incompleteness (44% with <75% variables filled) were noted.
- Gastrointestinal ADRs were most common (60%), with 10 serious ADRs and 18 drug withdrawals recorded. Patient outcomes included recovery (59.5%) and ongoing recovery (35.5%).
Conclusions:
- Current antimicrobial ADR reporting is characterized by inconsistency, significant delays, and incomplete data.
- The findings highlight the need for enhanced pharmacovigilance strategies, including active reporting mechanisms.
- Establishing clear performance targets is recommended to improve the quality and timeliness of ADR reporting for better patient safety.
More Related Videos
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
06:54Author Spotlight: Understanding and Detecting Environmental Antimicrobial Resistance by Combining Culture-Based Techniques and Genomics
Published on: July 19, 2024
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
Antimicrobial Effectiveness
Development of Antibiotic Resistance